Proteins and Peptides

23 August 2016

Hansa Medical: Top line results from the Swedish ongoing Phase II study with IdeS in sensitized patients presented

22 August 2016

Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD

21 August 2016

Sanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

18 August 2016

Portola Pharmaceuticals Receives Complete Response Letter from FDA for Biologics License Application for AndexXa™ (andexanet alfa)

18 August 2016

JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis

18 August 2016

CollPlant Reports Positive Final Extended Clinical Trial Results with Vergenix™STR for Treatment of Tendinopathy

16 August 2016

Aurinia Pharmaceuticals announces voclosporin meets primary endpoint in phase IIb AURA-LV study in lupus nephritis

12 August 2016

Ascendis Pharma A/S Initiates Phase 3 Registration Trial for TransCon Growth Hormone in Children with Growth Hormone Deficiency

12 August 2016

Prometic completes patients’ enrolment in pivotal plasminogen phase 2/3 clinical trial

12 August 2016

Phase II results with dasiglucagon (ZP4207) support its potential for use in a ready-to-use rescue pen to treat severe hypoglycemia in diabetes

10 August 2016

Coherus BioSciences Submits 351(k) Biologics License Application to U.S. Food and Drug Administration for CHS-1701 (Pegfilgrastim Biosimilar Candidate)

10 August 2016

Cardiome Announces XYDALBA™ Single Dose Infusion Approval by European Medicines Agency

5 August 2016

Merck Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for MK-1293, an Investigational Follow-On Biologic Insulin Glargine

1 August 2016

Ipsen Announces FDA Approval of Dysport® (abobotulinumtoxinA) for Injection for the Treatment of Lower Limb Spasticity in Children Aged Two and Older

30 July 2016

First Patient Enrolled in Mallinckrodt Phase 3 Terlipressin Trial

28 July 2016

Sanofi Receives FDA Approval of AdlyxinTM for Treatment of Adults with Type 2 Diabetes

26 July 2016

CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the World Federation of Hemophilia 2016 World Congress

26 July 2016

Eisai And Halozyme Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20

25 July 2016

Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA

21 July 2016

Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency

20 July 2016

Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer

19 July 2016

Hansa Medical Initiates Pivotal Multicenter Study in the US with IdeS for Treatment of Refractory Highly Sensitized Kidney Patients

18 July 2016

U.S. FDA Approves CSL Behring’s Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE)

18 July 2016

Pharming Announces Positive Results from Randomized Controlled Trial with RUCONEST® for HAE Prophylaxis

15 July 2016

Ultragenyx Announces Positive Topline Data from Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

14 July 2016

Panther Biotechnology Announces the Initiation of Formal Development of Transferrin Doxorubicin Conjugate

14 July 2016

Alexion Presents New SBC-103 (rhNAGLU enzyme) Phase 1/2 Data on Brain MRI and Neurocognitive Assessments in Patients with Mucopolysaccharidosis IIIB (MPS IIIB)

11 July 2016

Coherus Announces Positive Topline Results for CHS-1701 (Pegfilgrastim Biosimilar Candidate) Pharmacokinetic and Pharmacodynamic Biosimilarity Study

7 July 2016

Akari Therapeutics Announces Positive Interim Update from Phase Ib Trial Demonstrating Sustained Complement Inhibition Using Once-Daily Subcutaneous Maintenance Dosing with Coversin

7 July 2016

Shire Receives Extension of Market Authorization in Europe for Revestive▼ (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review

Eculizumab (Soliris) Biosimilars & Biosuperiors Pipeline Review

FcRn Inhibitors Pipeline Review

EpCAM-Targeted Antibodies Pipeline Review

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

TL1A Inhibitor Pipeline Review

Ustekinumab (Stelara) Biosimilars Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Folate Receptor alpha (FRα) Targeted Therapy Pipeline Review

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis